LEADER 02324nas--2200661---4500 001 990000009260203316 005 20100917114750.0 011 $a1683-142X 035 $a0000926 035 $aUSA010000926 035 $a(ALEPH)000000926USA01 035 $a0000926 100 $a2000091412005----km-y0ITAy0103----ba 101 0 $aeng 102 $aIE 110 $aafaz---|||| 200 1 $aAnnual energy and transport review$fEuropean commission, Directorate-general for energy and transport 207 $a2003- 210 $aLuxembourg$cOffice for official publications of the European Communities$d2005- 215 $av.$d30 cm$eCD-Rom 326 $aAnnuale 601 02$aComunit? europee$xPolitica energetica$xPeriodici 606 0 $aEnergia$xStatistiche internazionali$xPeriodici 676 $a333.79094 699 $a08.11$bPolitica energetica 712 02$aCOMMISSIONE EUROPEA :$bDirezione generale Energia e trasporti 801 0$aIT$bsalbc$gISBD 856 4$uhttp://europe.eu.int/comm/dgs/energy_transport/figures/energy_review_2003/index_en.htm$4.$zAccesso libero online 912 $a990000009260203316 958 $aCDE$bCDE / ANE$c2005- 959 $aSE 969 $aCDE 979 $c20000914$lUSA01$h1706 979 $c20000919$lUSA01$h1046 979 $c20000919$lUSA01$h1519 979 $c20001019$lUSA01$h1053 979 $c20001019$lUSA01$h1450 979 $c20001019$lUSA01$h1458 979 $c20001019$lUSA01$h1535 979 $c20001024$lUSA01$h1511 979 $c20001027$lUSA01$h1520 979 $c20001110$lUSA01$h1708 979 $c20001124$lUSA01$h1204 979 $c20020403$lUSA01$h1608 979 $aPATRY$b90$c20040406$lUSA01$h1602 979 $aPATRY$b90$c20060718$lUSA01$h1715 979 $aPATRY$b90$c20060718$lUSA01$h1717 979 $aPATRY$b90$c20060718$lUSA01$h1730 979 $aMARIAS$b90$c20080218$lUSA01$h1623 979 $aMARIAS$b90$c20080218$lUSA01$h1624 979 $aMARIAS$b90$c20080221$lUSA01$h1119 979 $aMARIAS$b90$c20090617$lUSA01$h1253 979 $aMARIAS$b90$c20090617$lUSA01$h1259 979 $aMARIAS$b90$c20090617$lUSA01$h1303 979 $aMARIAS$b90$c20100415$lUSA01$h1145 979 $aMARIAS$b90$c20100917$lUSA01$h1147 996 $aAnnual energy and transport review$9866398 997 $aUNISA LEADER 03313nam 2200637 a 450 001 9910792058803321 005 20200520144314.0 010 $a1-299-27682-2 010 $a2-84254-237-1 024 7 $a10.1051/978-2-84254-237-5 035 $a(CKB)2560000000099461 035 $a(EBL)3155343 035 $a(SSID)ssj0000906519 035 $a(PQKBManifestationID)11536131 035 $a(PQKBTitleCode)TC0000906519 035 $a(PQKBWorkID)10843950 035 $a(PQKB)10824750 035 $a(MiAaPQ)EBC3155343 035 $a(Au-PeEL)EBL3155343 035 $a(CaPaEBR)ebr10667713 035 $a(CaONFJC)MIL458932 035 $a(OCoLC)922991221 035 $a(DE-B1597)634993 035 $a(DE-B1597)9782842542375 035 $a(MiAaPQ)EBC7156049 035 $a(Au-PeEL)EBL7156049 035 $a(OCoLC)1355220062 035 $a(OCoLC)834607434 035 $a(PPN)176628622 035 $a(EXLCZ)992560000000099461 100 $a20130313d2012 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 04$aThe clinibook$b[electronic resource] $eclinical gene transfer : state of the art /$fedited by Odile Cohen-Haguenauer 210 $aParis $cEDP Sciences$d2012 215 $a1 online resource (589 p.) 300 $aDescription based upon print version of record. 311 $a2-84254-171-5 320 $aIncludes bibliographical references and index. 327 $apt. 1. Technologies and pre-clinical studies -- pt. 2. Clinical trials and regulatory issues. 330 $aThis book provides a 2012 reference for state-of-the-art gene transfer technology and the different aspects of its clinical translation with a focus on European-based initiatives. As examples of successful outcomes, recent clinical trials are presented together with Ethical, Safety and Regulatory issues, which are discussed. The broad range of various technologies is covered whether addressing direct in vivo gene transfer like with AAV, Adeno or non-viral vectors or ex-vivo genetically engineered cells including induced pluripotent stem cells (iPS) with integrating vectors such as retrovirus, lentivirus or transposon-derived systems. The critical path to clinical implementation is covered in the second part describing currently available tools - such as molecular imaging, ex-vivo organ cultures and high-throughput technologies used for evaluation of criteria towards a go-or-no go decision to move to the clinic; in addition, utmost salient biosafety and immunotoxicology aspects are discussed. This book is ideal for postgraduates, undergraduates, scientists, clinicians, regulators and patients' advocacy groups looking for states-of-the-art information as well as emerging prospects - including gene targeting and homologous recombination - in gene transfer intended for clinical translation. 606 $aGenetic transformation 615 0$aGenetic transformation. 676 $a571.96 700 $aCohen-Haguenauer$b Odile, $4aut$4http://id.loc.gov/vocabulary/relators/aut$01087562 701 $aCohen-Haguenauer$b Odile$01087562 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910792058803321 996 $aThe clinibook$93823776 997 $aUNINA